From Financial Modeling Prep: 2025-02-03 11:52:00

IDEXX Laboratories (NASDAQ:IDXX) exceeded Q4 expectations, boosting stock by 10%. Earnings per share hit $2.62, surpassing estimates of $2.39. Revenue rose 6% to $954.28 million, beating predictions of $933.38 million. CAG segment saw 6% revenue growth, with CAG Diagnostics up 7% organically, showcasing strong demand for veterinary solutions.

2025 outlook for IDEXX is positive, with revenue forecasted between $4.05 billion and $4.17 billion, showing 4-7% growth. Adjusted earnings per share predicted to be $11.74 to $12.24. Expectations include steady volume growth and a 4-4.5% pricing benefit, supporting continued business expansion.



Read more at Financial Modeling Prep:: IDEXX Laboratories Surges 10% on Strong Q4 Earning…